Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Characterization of surface modified glycerol/silk fibroin film for application to corneal endothelial cell regeneration.

Song JE, Sim BR, Jeon YS, Kim HS, Shin EY, Carlomagno C, Khang G.

J Biomater Sci Polym Ed. 2018 Oct 16:1-17. doi: 10.1080/09205063.2018.1535819. [Epub ahead of print]

PMID:
30324858
2.

Breath Figures decorated silicon oxinitride ceramic surfaces with controlled Si ions release for enhanced osteoinduction.

Carlomagno C, Motta A, Sorarù G, Aswath P, Migliaresi C, Maniglio D.

J Biomed Mater Res B Appl Biomater. 2018 Oct 14. doi: 10.1002/jbm.b.34221. [Epub ahead of print]

PMID:
30318728
3.

Multiple treatment lines and prognosis in metastatic colorectal cancer patients.

Carlomagno C, De Stefano A, Rosanova M, De Falco S, Attademo L, Fiore G, De Placido S.

Cancer Metastasis Rev. 2018 Jul 12. doi: 10.1007/s10555-018-9748-7. [Epub ahead of print] Review.

PMID:
30003458
4.

Enhanced retinal pigment epithelium (RPE) regeneration using curcumin/alginate hydrogels: In vitro evaluation.

Park JH, Shin EY, Shin ME, Choi MJ, Carlomagno C, Song JE, Khang G.

Int J Biol Macromol. 2018 Oct 1;117:546-552. doi: 10.1016/j.ijbiomac.2018.05.127. Epub 2018 May 18.

PMID:
29782973
5.

A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy.

Attademo L, De Falco S, Rosanova M, Esposito M, Mazio F, Foschini F, Santaniello A, Fiore G, Matano E, Manganelli F, Carlomagno C.

Medicine (Baltimore). 2018 Mar;97(9):e0011. doi: 10.1097/MD.0000000000010011.

6.

Identification of a novel truncating mutation in PALB2 gene by a multigene sequencing panel for mutational screening of breast cancer risk-associated and related genes.

Guacci A, Cordella A, Rocco T, Giurato G, Nassa G, Rizzo F, Carlomagno C, Pepe S, Tarallo R, Weisz A.

J Clin Lab Anal. 2018 Feb 27. doi: 10.1002/jcla.22418. [Epub ahead of print]

PMID:
29484706
7.

Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report.

Nunziato M, Starnone F, Lombardo B, Pensabene M, Condello C, Verdesca F, Carlomagno C, De Placido S, Pastore L, Salvatore F, D'Argenio V.

Int J Mol Sci. 2017 Nov 22;18(11). pii: E2487. doi: 10.3390/ijms18112487.

8.

Discordance in RAS mutations between primary colon tumor and metastases: a real event or a matter of methodology?

De Stefano A, Rosanova M, Malapelle U, Martini M, De Falco S, Attademo L, Fiore G, Cenci T, Bellevicine C, De Placido S, Troncone G, Carlomagno C.

Int J Biol Markers. 2017 Oct 31;32(4):e474-e477. doi: 10.5301/ijbm.5000273.

PMID:
28665451
9.

Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study.

Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S.

Oncologist. 2017 May;22(5):601-608. doi: 10.1634/theoncologist.2016-0246. Epub 2017 Apr 19.

10.

Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer.

Pensabene M, Condello C, Carlomagno C, De Placido S, Liccardo R, Duraturo F.

Hered Cancer Clin Pract. 2016 Sep 6;14(1):18. doi: 10.1186/s13053-016-0054-5. eCollection 2016.

11.

A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).

Avallone A, Piccirillo MC, Aloj L, Nasti G, Delrio P, Izzo F, Di Gennaro E, Tatangelo F, Granata V, Cavalcanti E, Maiolino P, Bianco F, Aprea P, De Bellis M, Pecori B, Rosati G, Carlomagno C, Bertolini A, Gallo C, Romano C, Leone A, Caracò C, de Lutio di Castelguidone E, Daniele G, Catalano O, Botti G, Petrillo A, Romano GM, Iaffaioli VR, Lastoria S, Perrone F, Budillon A.

BMC Cancer. 2016 Feb 8;16:69. doi: 10.1186/s12885-016-2102-y.

12.

Less frequently mutated genes in colorectal cancer: evidences from next-generation sequencing of 653 routine cases.

Malapelle U, Pisapia P, Sgariglia R, Vigliar E, Biglietto M, Carlomagno C, Giuffrè G, Bellevicine C, Troncone G.

J Clin Pathol. 2016 Sep;69(9):767-71. doi: 10.1136/jclinpath-2015-203403. Epub 2016 Jan 21.

13.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.

Lancet Oncol. 2015 Oct;16(13):1306-15. doi: 10.1016/S1470-2045(15)00122-9. Epub 2015 Aug 31.

PMID:
26338525
14.

Next-generation sequencing in the genomic profiling of synchronous colonic carcinomas: comment on Li et al (2015).

Malapelle U, De Stefano A, Carlomagno C, Bellevicine C, Troncone G.

J Clin Pathol. 2015 Nov;68(11):946-7. doi: 10.1136/jclinpath-2015-203205. Epub 2015 Jul 2. No abstract available.

PMID:
26139632
15.

UbcH10 expression can predict prognosis and sensitivity to the antineoplastic treatment for colorectal cancer patients.

Cacciola NA, Calabrese C, Malapelle U, Pellino G, De Stefano A, Sepe R, Sgariglia R, Quintavalle C, Federico A, Bianco A, Uchimura Bastos A, Milone M, Bellevicine C, Milone F, Carlomagno C, Selvaggi F, Troncone G, Fusco A, Pallante P.

Mol Carcinog. 2016 May;55(5):793-807. doi: 10.1002/mc.22322. Epub 2015 Apr 27.

PMID:
25917796
16.

KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.

Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G.

J Clin Pathol. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21.

PMID:
25609577
17.

Bevacizumab maintenance in metastatic colorectal cancer: How long?

De Stefano A, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Di Pietro F, Pepe S, De Placido S, Carlomagno C.

World J Clin Cases. 2014 Nov 16;2(11):717-23. doi: 10.12998/wjcc.v2.i11.717.

18.

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A.

N Engl J Med. 2014 Oct 23;371(17):1609-18. doi: 10.1056/NEJMoa1403108.

19.

Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.

Sabbatino F, Fusciello C, Somma D, Pacelli R, Poudel R, Pepin D, Leonardi A, Carlomagno C, Della Vittoria Scarpati G, Ferrone S, Pepe S.

Cytometry A. 2014 Nov;85(11):953-61. doi: 10.1002/cyto.a.22563. Epub 2014 Sep 2.

20.

Analysis of differential miRNA expression in primary tumor and stroma of colorectal cancer patients.

Della Vittoria Scarpati G, Calura E, Di Marino M, Romualdi C, Beltrame L, Malapelle U, Troncone G, De Stefano A, Pepe S, De Placido S, D'Incalci M, Marchini S, Carlomagno C.

Biomed Res Int. 2014;2014:840921. doi: 10.1155/2014/840921. Epub 2014 Jul 10.

21.

Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer.

De Stefano A, Carlomagno C.

World J Gastroenterol. 2014 Aug 7;20(29):9732-43. doi: 10.3748/wjg.v20.i29.9732.

22.

Adjuvant treatment for locally advanced rectal cancer patients after preoperative chemoradiotherapy: when, and for whom?

De Stefano A, Moretto R, Bucci L, Pepe S, Romano FJ, Cella AC, Attademo L, Rosanova M, De Falco S, Fiore G, Raimondo L, De Placido S, Carlomagno C.

Clin Colorectal Cancer. 2014 Sep;13(3):185-91. doi: 10.1016/j.clcc.2014.05.004. Epub 2014 Jun 26.

PMID:
25080847
23.

Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer.

Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, Comella G, Amadori D, Pinto C, Carlomagno C, Nitti D, Daniele B, Mini E, Poli D, Santoro A, Mosconi S, Casaretti R, Boni C, Pinotti G, Bidoli P, Landi L, Rosati G, Ravaioli A, Cantore M, Di Fabio F, Aitini E, Marchet A; ITACA-S (Intergroup Trial of Adjuvant Chemotherapy in Adenocarcinoma of the Stomach Trial) Study Group.

Ann Oncol. 2014 Jul;25(7):1373-8. doi: 10.1093/annonc/mdu146. Epub 2014 Apr 12.

PMID:
24728035
24.

Basaloid squamous cell carcinoma: a rare tumor at the esophagogastric junction and an unexpected durable complete response to FOLFOX-4.

Cella CA, Carlomagno C, Lordick F, Moretto R, De Stefano A, Raimondo L, D'Armiento M, Camera L, Guadagno E, Attademo L, Feliciano S, Matano E.

Oncol Res Treat. 2014;37(1-2):55-8. doi: 10.1159/000358159. Epub 2014 Jan 24.

PMID:
24613910
25.

Ipilimumab in the treatment of metastatic melanoma: management of adverse events.

Della Vittoria Scarpati G, Fusciello C, Perri F, Sabbatino F, Ferrone S, Carlomagno C, Pepe S.

Onco Targets Ther. 2014 Feb 19;7:203-9. doi: 10.2147/OTT.S57335. eCollection 2014. Review.

26.

A prognostic model comprising pT stage, N status, and the chemokine receptors CXCR4 and CXCR7 powerfully predicts outcome in neoadjuvant resistant rectal cancer patients.

D'Alterio C, Avallone A, Tatangelo F, Delrio P, Pecori B, Cella L, Pelella A, D'Armiento FP, Carlomagno C, Bianco F, Silvestro L, Pacelli R, Napolitano M, Iaffaioli RV, Scala S.

Int J Cancer. 2014 Jul 15;135(2):379-90. doi: 10.1002/ijc.28689. Epub 2014 Jan 10.

27.

Diagnostic utility of BRAFV600E mutation testing in thyroid nodules in elderly patients.

Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Pepe S, Zeppa P, Tonacchera M, Vitale M.

BMC Surg. 2013;13 Suppl 2:S37. doi: 10.1186/1471-2482-13-S2-S37. Epub 2013 Oct 8.

28.

Pulmonary sequestration presented as massive left hemothorax and associated with primary lung sarcoma.

Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Garzi A, Vitale M.

BMC Surg. 2013;13 Suppl 2:S34. doi: 10.1186/1471-2482-13-S2-S34. Epub 2013 Oct 8.

29.

An unusual case of primary choriocarcinoma of the lung.

Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Garzi A, Vitale M.

BMC Surg. 2013;13 Suppl 2:S33. doi: 10.1186/1471-2482-13-S2-S33. Epub 2013 Oct 8.

30.

Migration of surgical clips through a right lobectomy stump mimicking an asthmatic syndrome.

Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Danzi M, Amato B, Garzi A, Vitale M.

BMC Surg. 2013;13 Suppl 2:S32. doi: 10.1186/1471-2482-13-S2-S32. Epub 2013 Oct 8.

31.

Unusual case of exacerbation of sub-acute descending necrotizing mediastinitis.

Di Crescenzo V, Laperuta P, Napolitano F, Carlomagno C, Danzi M, Amato B, Garzi A, Vitale M.

BMC Surg. 2013;13 Suppl 2:S31. doi: 10.1186/1471-2482-13-S2-S31. Epub 2013 Oct 8.

32.

Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review.

Guerra A, Di Crescenzo V, Garzi A, Cinelli M, Carlomagno C, Tonacchera M, Zeppa P, Vitale M.

BMC Surg. 2013;13 Suppl 2:S44. doi: 10.1186/1471-2482-13-S2-S44. Epub 2013 Oct 8. Review.

33.

Cytological diagnosis of adult-type fibrosarcoma of the neck in an elderly patient. Report of one case and review of the literature.

Cozzolino I, Caleo A, Di Crescenzo V, Cinelli M, Carlomagno C, Garzi A, Vitale M.

BMC Surg. 2013;13 Suppl 2:S42. doi: 10.1186/1471-2482-13-S2-S42. Epub 2013 Oct 8. Review.

34.

Cytological diagnosis of thyroid nodules in Hashimoto thyroiditis in elderly patients.

Caleo A, Vigliar E, Vitale M, Di Crescenzo V, Cinelli M, Carlomagno C, Garzi A, Zeppa P.

BMC Surg. 2013;13 Suppl 2:S41. doi: 10.1186/1471-2482-13-S2-S41. Epub 2013 Oct 8.

35.

KRAS testing in metastatic colorectal carcinoma: challenges, controversies, breakthroughs and beyond.

Malapelle U, Carlomagno C, de Luca C, Bellevicine C, Troncone G.

J Clin Pathol. 2014 Jan;67(1):1-9. doi: 10.1136/jclinpath-2013-201835. Epub 2013 Sep 10. Review.

PMID:
24022727
36.

Human herpes virus associated with Hashimoto's thyroiditis.

Di Crescenzo V, D'Antonio A, Tonacchera M, Carlomagno C, Vitale M.

Infez Med. 2013 Sep;21(3):224-8.

37.

FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma: a monoinstitutional experience.

Moretto R, Raimondo L, De Stefano A, Cella CA, Matano E, De Placido S, Carlomagno C.

Anticancer Drugs. 2013 Oct;24(9):980-5. doi: 10.1097/CAD.0b013e328364e66b.

PMID:
23928570
38.

Concomitant interferon-alpha and chemotherapy in hepatitis C and colorectal cancer: a case report.

Gentile I, De Stefano A, Di Flumeri G, Buonomo AR, Carlomagno C, Morisco F, De Placido S, Borgia G.

In Vivo. 2013 Jul-Aug;27(4):527-9.

PMID:
23812225
39.

EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.

Malapelle U, Bellevicine C, De Luca C, Salatiello M, De Stefano A, Rocco D, de Rosa N, Vitiello F, Russo S, Pepe F, Iaccarino A, Micheli P, Illiano A, Carlomagno C, Piantedosi FV, Troncone G.

Cancer Cytopathol. 2013 Oct;121(10):552-60. doi: 10.1002/cncy.21322. Epub 2013 Jun 18.

40.

Multidisciplinary approach to patient with malignant melanoma.

Scarpati GD, Fusciello C, Sabbatino F, Ferrone S, Caponigro F, Perri F, Carlomagno C, Pepe S.

Anticancer Agents Med Chem. 2013 Jul 1;13(6):887-900.

PMID:
23272971
41.

Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models.

Rosa R, Marciano R, Malapelle U, Formisano L, Nappi L, D'Amato C, D'Amato V, Damiano V, Marfè G, Del Vecchio S, Zannetti A, Greco A, De Stefano A, Carlomagno C, Veneziani BM, Troncone G, De Placido S, Bianco R.

Clin Cancer Res. 2013 Jan 1;19(1):138-47. doi: 10.1158/1078-0432.CCR-12-1050. Epub 2012 Nov 19.

42.

Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective.

Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G.

J Clin Pathol. 2012 Oct;65(10):940-4. Epub 2012 Aug 7.

43.

KRAS mutation detection by high-resolution melting analysis significantly predicts clinical benefit of cetuximab in metastatic colorectal cancer.

Malapelle U, Carlomagno C, Salatiello M, De Stefano A, De Luca C, Bianco R, Marciano R, Cimminiello C, Bellevicine C, De Placido S, Troncone G.

Br J Cancer. 2012 Aug 7;107(4):626-31. doi: 10.1038/bjc.2012.275. Epub 2012 Jul 17.

44.

Primary hepatic lymphoma in a patient with previous rectal adenocarcinoma: a case report and discussion of etiopathogenesis and diagnostic tools.

Raimondo L, Ferrara I, Stefano AD, Cella CA, D'Armiento FP, Ciancia G, Moretto R, Renzo AD, Carlomagno C.

Int J Hematol. 2012 Mar;95(3):320-3. doi: 10.1007/s12185-012-1025-x. Epub 2012 Feb 21.

PMID:
22351247
45.

A specific miRNA signature correlates with complete pathological response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Della Vittoria Scarpati G, Falcetta F, Carlomagno C, Ubezio P, Marchini S, De Stefano A, Singh VK, D'Incalci M, De Placido S, Pepe S.

Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):1113-9. doi: 10.1016/j.ijrobp.2011.09.030. Epub 2011 Dec 13.

PMID:
22172905
46.

Fasting glucose and treatment outcome in breast and colorectal cancer patients treated with targeted agents: results from a historic cohort.

Barba M, Sperati F, Stranges S, Carlomagno C, Nasti G, Iaffaioli V, Caolo G, Mottolese M, Botti G, Terrenato I, Vici P, Serpico D, Giordano A, D'Aiuto G, Crispo A, Montella M, Capurso G, Delle Fave G, Fuhrman B, Botti C, De Placido S.

Ann Oncol. 2012 Jul;23(7):1838-45. doi: 10.1093/annonc/mdr540. Epub 2011 Nov 18.

47.

Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials.

Carlomagno C, Daniele G, Bianco R, Marciano R, Damiano V, Matano E, Nappi L, Pepe S, DE Placido S, Tortora G.

Exp Ther Med. 2011 May;2(3):449-455. Epub 2011 Feb 25.

48.

Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients.

De Stefano A, Carlomagno C, Pepe S, Bianco R, De Placido S.

Cancer Chemother Pharmacol. 2011 Nov;68(5):1207-13. doi: 10.1007/s00280-011-1604-1. Epub 2011 Mar 16.

PMID:
21409384
49.

Guillain-Barre Syndrome Associated with Gastric Cancer: Paraneoplastic Syndrome or Immunological Disorder?

Colantuoni M, Matano E, Alfieri S, De Placido S, Carlomagno C.

World J Oncol. 2010 Dec;1(6):247-249. doi: 10.4021/wjon259w. Epub 2011 Jan 1.

50.

Predictive factors of complete response to neoadjuvant chemoradiotherapy in patients with rectal cancer.

Carlomagno C, Pepe S, D'Armiento FP, D'Armiento M, Cannella L, De Stefano A, Crispo A, Giordano M, De Placido S.

Oncology. 2010;78(5-6):369-75. doi: 10.1159/000320464. Epub 2010 Aug 26.

PMID:
20798559

Supplemental Content

Loading ...
Support Center